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ABSTRACT
Multiple types of regulation are used by cells and
viruses to control alternative splicing. In murine
leukemia virus, accessibility of the 5’ splice site
(ss) is regulated by an upstream region, which can
fold into a complex RNA stem–loop structure.
The underlying sequence of the structure itself is
negligible, since most of it could be functionally
replaced by a simple heterologous RNA stem–loop
preserving the wild-type splicing pattern. Increasing
the RNA duplex formation between U1 snRNA and
the 5’ss by a compensatory mutation in position +6
led to enhanced splicing. Interestingly, this mutation
affects splicing only in the context of the secondary
structure, arguing for a dynamic interplay between
structure and primary 5’ss sequence. The reduced
5’ss accessibility could also be counteracted
by recruiting a splicing enhancer domain via a
modified MS2 phage coat protein to a single
binding site at the tip of the simple RNA stem–
loop. The mechanism of 5’ss attenuation was
revealed using hyperstable U1 snRNA mutants,
showing that restricted U1 snRNP access is the
cause of retroviral alternative splicing.
INTRODUCTION
Alternative splicing extensively expands the human
transcriptome (1) and proteome, giving rise to roughly
100000 protein isoforms from only 25000 genes (2).
In retroviruses a single pre-mRNA corresponding to the
complete genome also undergoes alternative splicing to
express all viral genes (3).
The splicing reaction is executed by the spliceosome (4).
The core of the spliceosome consists of ﬁve small nuclear
RNPs (U snRNPs; 5), some of which participate in splice
site recognition via RNA:RNA interactions (6,7). The ﬁrst
step towards mRNA splicing is the recognition of the 50ss
by the free, complementary 50 end of U1 snRNA (8,9).
Therefore, the hydrogen bonding pattern between all
11nt of the 50ss and U1 snRNA determines the intrinsic
strength of the 50ss and thus contributes to its recognition
and frequency of usage, creating a ﬁrst layer of regulation
(10,11).
In contrast to yeast, where almost all splice sites match
the consensus sequence (12), splice sites in retroviral and
mammalian genomes are much more degenerated and
recognition is frequently assisted by a number of splicing
regulatory proteins (13). Accordingly, regions in
proximity to splice sites often represent exonic or
intronic splicing enhancers (ESE, ISE; 14), or silencers
(ESS, ISS; 15,16). These elements modulate the intrinsic
strength of splice sites mostly via recruitment of splicing
factors like SR proteins or hnRNPs (17). The eﬃciency of
splice sites can also be modulated by RNA structure
(18,19). Either folding of the structure competes directly
with formation of the U1 snRNA:50ss RNA duplex or
indirectly by masking binding sites of splicing regulatory
proteins (20). Finally, transcriptional elongation can also
regulate alternative splicing, illustrating the close
connection between splicing and transcription (21).
Retroviruses represent very valuable model systems for
studying alternative splicing (22). While they synthesize
only one polycistronic primary transcript, which
undergoes alternative splicing for full viral gene
expression (Figure 1A; 23), retroviruses also need to
tightly control the use of their splice sites to ensure
optimal levels of unspliced versus spliced RNAs (3). The
unspliced or genomic RNA is packaged into progeny virus
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and enzymatic proteins Gag and Pol, whereas the spliced
RNA encodes the envelope protein (Env; Figure 1A).
The correct ratio of Gag and Env partly determines viral
infectivity. HIV splicing is highly regulated by ESEs or
ESSs [(24–26); reviewed in (27)] and by weak
polypyrimidine tracts (PPTs), which are interrupted by
weakening purines (28). In one case reported, a PPT is
additionally attenuated by a secondary structure (29).
For simple retroviruses such as Rous sarcoma virus
(RSV) or murine leukemia virus (MLV), alternative
splicing has also been attributed to weak 30ss (30–32). In
addition, RSV harbors a decoy 50ss, which redirects
splicing activity from the authentic 50ss to a nonproductive
one (33).
We could previously show that in MLV the 50ss instead
of the 30ss is negatively regulated via upstream sequences,
which can form a secondary structure. Moreover, the
stability and integrity of this structure correlates with
50ss attenuation (34). We now demonstrate that the
restriction exerted by this upstream RNA secondary
structure depends on limited complementarity between
U1 snRNA and the 50ss at position +6. We show that
the RNA secondary structure-mediated U1 snRNA
restriction could be counterbalanced by either increasing
complementarity to U1 snRNA or SR protein-mediated
stabilization of the 50ss:U1 snRNA duplex. The latter was
accomplished by an improved MS2-tethering system,
which exerts a high aﬃnity to a single stem–loop
binding site. A heterologous RNA stem loop of com-
parable thermodynamic stability could replace the wild-
type structure and preserve the splicing pattern.
Interestingly, low complementarity to U1 snRNA aﬀects
splicing only in the context of the secondary structure,
arguing for a dynamic interplay between structure and
intrinsic strength of the 50ss.
MATERIALS AND METHODS
Plasmids
All retroviral vector plasmids were derived from pSF91
(35). The mutants sm3 (stem–loop mutant 3),
compensatory mutants thereof (sm3comp) and the
deletion of the primer binding site (dPBS) were
described previously (34). All overlap PCRs used the
outer primers XbaI and ApaI (34) to generate the ﬁnal
PCR fragment, which was cloned into the XbaI/ApaI
sites of SF91. Vectors carrying the C6U 50ss mutation
were cloned by overlapping PCRs using SF91, SF91sm3,
SF91dPBS and SF91stem–loop as a template (fw: 50-TAA
GTT GGC CAG CGG TCG TTT CG-30; rv: 50-GGC
CAA CTT ACC TCC CGG C-30). For insertion of the
heterologous stem–loop (SF91stem–loop) into the leader
region of SF91, the KpnI/MscI fragment was replaced by
a PCR product including the heterologous stem–loop
sequences (fw: 50-GTA CGG TAC CGT ATT CCC
AAT AAA GCC TCT TGC TGT TTG CAT CCG
AAT CGT GGA GGT CAA GAA TTC GCG GAC
ACC ATC-30; rv: 50-GCA TCC TGG CCA GCT TAC
CTC CCG GCG GAG GTC AAG AAT TCG CGG
ACC CTG ATG GTG TCC GCG AAT TCT TGA
CCT CCA CGA TTC-30). The extended stem–loop was
generated by introducing 20 additional base pairs into the
EcoRI sites of SF91stem–loop (fw: 50-[Phos] AAT TCG
ATA TCC CGT GCG GAC ACC ATC AGG GTC CGC
ACG GGA TAT CG-30; rv: 50-[Phos] CGA TAT CCC
GTG CGG ACC CTG ATG GTG TCC GCA CGG
GAT ATC GAA TT-30) by ligation. By using the
SF91stem–loop as a template, the SF91stem–loop
antisense mutant (fw: 50-CGC CTC CAG TTC TTA
AGC GCC TCG GGA GGT AAG CTG GCC AGC
GGT CGT TTC G-30; rv: 50-AGG CGC TTA AGA
ACT GGA GGC GCC CTG ATG GTG TCC GCG
AAT TCT TGA C-30) was generated by overlapping
PCRs and the ﬁnal PCR product was cloned into the
XbaI/ApaI sites of SF91. The SCSenv HIV/MLV hybrid
constructs were also cloned by overlapping PCRs. The
50PCR product was generated by using SCS11 (36) as a
template (fw: 50-GCG GTA TAC GCT AGC TTA AGT
AG-30; rv: 50-TAC TTA CTG CCC GGC GGG GGG
GTC GGT G-30). To generate the 30PCR product
containing the HIV 50ss, NLenv was used as a template
(fw: 50-CCC CCC CGC CGG GCA GTA AGT AGT
ACA TGT AAT GC-30; rv: 50-GGT TGC TTC CTT
CCA CAC AGG TAC-30). Using the outer primers, the
ﬁnal PCR product was cloned into the Bst1107I/BstEII
sites of the NLCenv backbone (37). In order to transfer
the sm3 and the C6U mutation into an MLV provirus, an
AﬂII/PstI fragment of the respective SF91 plasmids was
generated and ligated into MOVSFGFP (34,38).
U1 snRNA mutants were cloned by PCR using a
reverse primer (rv: 50-CGC GGA TCC TCC ACT GTA
GGA TTA AC-30) including a BamHI restriction site and
diﬀerent forward primers containing the U1 mutations
ﬂanked by a BglII restriction site (fw U1G11C: 50-GCC
CGA AGA TCT CAT ACT TAC CTC GCA G-30;f wU 1
perfect: 50-GCC CGA AGA TCT CCA GCT TAC CTC
GCA G-30). The PCR products were cloned as a BamHI/
BglII fragment into the pUC19 U1wt plasmid (kind gift
from A. Weiner, Seattle, WA, USA).
For construction of plasmid SV SD4/SA7 NLS-MS2
SRp55pA, the BamHI/XhoI fragment of SV NLS-MS2
9G8 (39) was replaced by a PCR product generated with
primers (fw: 50-GGT GGA TCC CGC ACA AGC CAT
AGG CGA TC-30; rv: 50-AGA CTC GAG TTA ATC
TCT GGA ACT CGA CCT GG-30) and CMV myc
SRp55 (kindly provided by A. Cochrane, Toronto,
Canada) as a template. Plasmid SV NLS-MS2-SR has
been described previously (39). SV SD4/SA7 NLS-
MS2FG-SR and SVSD4/SA7 NLS-MS2 FG-
SRp55 were generated by substitution of the XmaI/
EcoRI fragment by a PCR-ampliﬁed fragment with
primers (fw: 50-GAC CCC GGG ATG GGG CCG
CAA AAA ACG CCG C-30 and rv: 50-TCG GAA TTC
GTA GCG AAA ATT GGA ATG GTT AGT TCC ATA
TTT AAG TAC GAA CGC CAG GCG CCT-30),
containing a deletion of the sequence encoding the
ﬂexible a-helical loop connecting the two b-strands
F and G (FG loop) within the MS2 coat protein, and
SV SD4/SA7 NLS-MS2-SR as a template.
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293T cells were grown in Dulbecco’s modiﬁed Eagle’s
medium supplemented with 10% fetal calf serum, 1mM
sodium pyruvate and 1% penicillin/streptomycin. The day
before transfection, 4 10
6 293T cells were seeded in a
10-cm plate. Transfections were performed using the
calcium phosphate precipitation method with 5mg of the
SF91 plasmid (10mg for proviral constructs). Medium
was changed 8h post-transfection, and the cells were
harvested 48h later. Transfection eﬃciency was
measured by FACS analysis and ranged between 40%
and 60% (FACSCalibur; Becton-Dickinson, Heidelberg,
Germany). The co-transfection assays (MS2 and U1) were
performed using 5mg SF91 plasmid and 10mg U1 plasmid
or 5mg MS2-plasmid. HeLaP4 cells (40) were cultured
under conditions identical to those for 293T cells. The
day before transfection, 6 10
5 HeLaP4 cells were
seeded in a 6-cm plate. Cells were transfected using the
ICAFectin
TM 441 DNA transfection reagent (Eurogentec,
Brussels, Belgium) and 2.75mg plasmid DNA. RNA was
harvested 36h later.
For virus production, 293T cells were transfected with
10mg of proviral plasmids. Supernatants were collected
36h and 48h after transfection and passed through a
0.22mm ﬁlter (Millipore, Schwalbach, Germany). Initial
titers were determined by transduction of 1 10
5 SC-1
cells (murine ﬁbroblasts) using serial dilutions in the
presence of 4mg/ml protamine sulfate. Cells were
centrifuged at 950g and 258C for 60min and incubated
for not more than 24h to avoid re-infection. Cells were
harvested and GFP-positive cells were counted by ﬂow
cytometry. GFP is encoded in frame with the MLV env
ORF (38). SC-1 cells were then infected with a multiplicity
of infection of 0.3. The spreading infection was monitored
using GFP ﬂuorescence and supernatants were collected at
90% GFP-positive cells. The supernatants were re-titrated
on SC-1 cells to determine the viral titers after replication
in murine cells.
RNA preparation and analysis
Preparation of total RNA, gel electrophoresis, blotting
and detection with a radiolabeled probe were performed
as described previously (41). The eGFP-speciﬁc probe
corresponds to the eGFP cDNA and was generated by
digestion of the SF91 plasmid with AgeI and EcoRI. To
detect 18S rRNA, a genomic fragment was PCR-ampliﬁed
and subcloned into pCR2.1 (Invitrogen, Karlsruhe,
Germany). The probes were radiolabeled using the
DecaLabel Kit (Fermentas, St. Leon-Rot, Germany).
RNA was quantiﬁed photometrically and 10mg were
used for northern blot analysis, if not stated otherwise.
Phosphoimager analysis
The diﬀerent RNA species were quantiﬁed by
phosphoimager analysis (Storm 820; GE Healthcare,
Chalfont St. Giles, UK) using a short and a longer
exposure. Only experiments where the fold enhancement
or splicing ratios remained constant over both exposure
times were processed. The percentage of unspliced RNA
was calculated using the following formula: [unspliced
RNA/(spliced RNA+unspliced RNA)] 100=%
unspliced RNA.
Reverse transcription and quantitative real-time PCR
analysis
For reverse transcription, 5mg total RNA were digested
using the Ambion TURBO
TM DNase (Austin, TX, USA).
500–800ng RNA were reverse transcribed using the
QuantiTect Reverse Transcription Kit (Qiagen, Hilden,
Germany). Quantitative PCR was performed on a
Stratagene Mx 3000P (La Jolla, CA, USA) using the
QuantiFast SYBR Green (Qiagen) PCR Kit. To detect
the unspliced RNA, fw primer 50-GAG GGT CTC CTC
AGA TTG ATT GAC-30 and rv primer 50-GAC AGA
CAC GAA ACG ACC GC-30 were used. To detect the
spliced RNA, the fw primer was combined with an exon
junction primer: 50-TGT AAG TGA GCT CCC GGC-30.
As a standard we used a U1 snRNA primer set (fw:
50-CTT ACC TGG CAG GGG AGA TAC-30 and rv:
50-GAA AGC GCG AAC GCA GTC-30).
Electromobility shift assay
Using SF91stem–loop and stem–loop antisense templates
(Figure 3A), PCR products were generated carrying a
T7 promoter. The products were ligated into pCR2.1.
T7 transcripts correspond exactly to the sequence
depicted in Figure 3A. The resulting plasmids were
linearized and approximately 500ng were used for
in vitro transcription using Ambion’s Maxiscript Kit in
the presence of 50mCi of [
32P]UTP (400Ci/mmol,
Hartmann Analytic, Braunschweig, Germany) and
unlabeled UTP to a ﬁnal concentration of 40mM. Free
nucleotides were removed by MoBiTec S300 columns
and probes were puriﬁed using denaturing PAGE. The
radiolabeled RNA probe (25000c.p.m.) was incubated
in 25mM Tris–HCl, pH 7.9, 5mM MgCl2, 10% (v/v)
glycerol, 0.4mM dithiothreitol, 0.5mM EDTA, 10U
RNAsin (Promega), 4mg BSA and 1mg of yeast tRNA
in a total volume of 15ml for 30min at 208C to allow
folding of the RNA structure followed by denaturing for
2min at 908C. Puriﬁed U1 snRNP was purchased from
Phadia (Freiburg, Germany). The puriﬁcation procedure
was performed using the original protocol from the
Lu ¨ hrmann laboratory (42). U1 snRNP was added
10min prior to loading on a 6% (60:1) polyacrylamide
gel run in Tris–borate–EDTA buﬀer. The presence of
U1 snRNA in the U1 snRNP fraction was assessed
using RT-PCR along with a U1 plasmid as a control
(Supplementary Figure 2).
Western blotting
Cells were resuspended in lysis buﬀer (ﬁnal concentration,
150mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1%
SDS, 100mM NaF, 10% glycerol, 10mM EDTA,
50mM Tris pH 8, 1mM PMSF, Protease Inhibitor
Cocktail Tablet; Roche, Mannheim, Germany) and
incubated on ice for 20min. The lysates were cleared by
centrifugation at 15000g for 10min. Twenty micrograms
protein were run on SDS–PAGE (10%), and transferred
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Germany). MLV capsid was detected by a polyclonal
rabbit anti-MLV p30 serum (kindly provided by C.
Stocking, Hamburg, Germany) diluted 1:5000 in PBS-
Tween, 0.1% and 5% dry milk. The membranes were re-
probed using a mouse anti-actin antibody (Millipore,
Schwalbach, Germany). Detection was carried out by
chemi-luminescence (West Pico, Pierce, Bonn, Germany).
Computer software tools
RNA folding analysis of the leader region and of
mutants thereof was performed using the mFOLD
software (43; web access: http://mfold.bioinfo.rpi.edu).
RNA structures were assembled using the XRNA
software (http://rna.ucsc.edu/rnacenter/xrna/xrna.html).
The intrinsic 50ss strength was determined using the
HBond-score algorithm (http://www.uni-duesseldorf.de/
rna/html/hbond_score.php). Statistical analysis was
performed using Graph Pad Prism 4 software.
RESULTS
Increasing 5’ splice site strength partially relieves the
restriction exerted by the secondary structure
In order to reveal the molecular requirements for the
previously described RNA secondary structure-mediated
restriction of the murine leukemia virus (MLV) 50ss, we
used our previously described splicing reporter SF91 (34).
This retroviral vector is derived from an MLV provirus
and contains the packaging signal (c) embedded in an
intron ﬂanked by the authentic MLV 50 and 30 splice
sites followed by eGFP as a marker gene (Figure 1A;
35). All reporter constructs were transiently transfected
into 293T cells and total RNA was analyzed by northern
blotting and quantiﬁed using a Phosphoimager. In
addition, we independently assessed the splicing ratios
by quantitative RT-PCR using the same RNAs.
We now considered whether the intrinsic strength of
the 50ss or its complementarity to U1 snRNA might
contribute to the splicing regulation exerted by the
secondary structure. Therefore, we converted position
+6 of the MLV 50ss from C to U (Figure 1B), thereby
increasing the complementarity from an HBond score of
17.1 to 19.1. The C6U mutant displayed a 2.5-fold
enhancement of splicing in the context of the secondary
structure (Figure 1C and D; lanes 1 and 2). In comparison,
mutations which exclusively prevent stem formation led to
an 8-fold enhancement of splicing (sm3, Figure 1B;
Figure 1C and D; compare lanes 2 and 3). These results
conﬁrm that, in a less structured region, fewer
complementary nucleotides to U1 snRNA are suﬃcient
to constitute an eﬃcient 50ss. A combination of the two
mutations led to an almost complete lack of unspliced
RNA (Figure 1C, lane 4). As shown in Figure 1D, the
phosphoimager data are highly comparable to the qRT-
PCR, although the latter tend to yield slightly higher
values for the unspliced RNA in general (Figure 1D,
black bars). Therefore, we continued to use northern
blotting in the subsequent experiments to be able to
detect cryptic splicing events as a possible result of the
introduced mutations.
To investigate whether increasing the 50ss:U1 snRNA
complementarity could also relieve the restriction of a
thermodynamically even more stable RNA secondary
structure, we used a deletion of the primer binding site
(Figure 1B), which folds into a more stable stem–loop
(G=–68.5kcal/mol in comparison to –61.4kcal/mol
for SF91wt) and shows a stronger attenuation of the
50ss (dPBS; Figure 1C, lane 5). Also in this context, the
C6U mutation enhanced splicing (Figure 1C, lane 6;
and Figure 1D). Both the C6U and dPBS mutations
seem to inﬂuence the transcript levels of the SF91 RNA
(Figures 1C and 3).
In summary, regulation at the 50ss occurs on two layers:
the primary splice site sequence and an upstream
secondary structure.
The regulation of splicing is conserved in a replication-
competent provirus
In order to conﬁrm that splicing in the provirus is also
regulated on two layers, secondary structure and primary
50ss sequence, we cloned two key splicing mutations,
namely sm3 (structural mutant; Figure 1C, lane 3) and
C6U (splice site mutant; Figure 1C, lane 2), into an
infectious MLV provirus (Figure 1A). Both types of
mutations yielded an enhancement of splicing identical
to that seen in the splicing reporter (Figure 2A). Even
though the provirus splices less eﬃciently than the
reporter, the magnitude of splicing enhancement is
maintained (Figure 2C). Oversplicing of the genomic
RNA should lead to reduced levels of full-length RNA
to be packaged into viral progeny and to lower amounts
of structural proteins since they are translated only from
the unspliced RNA. Western blot analysis of cell lysates
harvested from 293T cells revealed a correlation between
the splicing ratio and the amount of capsid (p30) protein
(Figure 2B). We also tested whether these mutations
hamper viral replication. Indeed, replication of the sm3
provirus in murine ﬁbroblast cells (SC-1) led to an
almost 4-fold decrease in viral titer compared to wild-
type MLV (Figure 2D). The C6U mutant showed only a
modest titer reduction in agreement with the viral RNA
and protein analysis. Thus, there is a correlation between
the extent of splicing and viral ﬁtness.
To sum up, the regulation of alternative splicing is
conserved in the context of the complete provirus and
mutations that severely aﬀect splicing ratios impede viral
replication.
The attenuating effect of the secondary structure is
transferable to a heterologous 5’ splice site
Next we asked: did the inhibitory secondary structure
evolve and function only in murine leukemia virus? In
addition, we wanted to rule out the possibility that
sequences far downstream of the 50ss are involved in its
attenuation. For this purpose, we used the previously
described HIV-NLenv system (Figure 3A; 44). Brieﬂy,
this subviral envelope expression system is based on the
HIV-1 proviral clone NL4-3. Using the Tat-independent
7432 Nucleic Acids Research, 2009, Vol. 37,No. 22CMV promoter instead of the viral LTR (NLCenv), the
construct expresses a sequence-identical HIV env mRNA,
which can be alternatively spliced to yield nef mRNA
(Figure 3A; 37). RNA analysis showed that NLCenv
displays alternative splicing due to the weak 30ss
upstream of nef (Figure 3C, lane 2; 20,44).
In order to transfer the splicing regulation from MLV
to a heterologous 50ss, we inserted the 50 leader sequence
of MLV (bases 1–203; Figure 1B) immediately upstream
of the HIV 50ss, thereby creating SCSenv (light grey box,
Figure 3A). SCSenv expresses an MLV/HIV fusion
transcript containing the MLV-derived secondary
structure (Figure 1B) followed by the HIV 50ss and
downstream env mRNA sequences. The proposed
secondary structure of the fusion transcript is depicted
in Figure 3B. The MLV RNA stem–loop may also force
the HIV 50ss into an inhibitory conformation. In addition,
we transferred two structural mutations (sm3 and dPBS;
Figure 1C) to SCSenv. For this experiment, we used
HeLaP4 cells, in which the NLenv system was established
(44), instead of 293T cells. Transfection into HeLaP4 cells
revealed that the MLV-derived sequences can also
strongly attenuate the HIV 50ss (Figure 3C, compare
lanes 2 and 3). The level of unspliced RNA was
enhanced 2.5-fold (Figure 3D) and exceeded the level of
50ss attenuation observed for the basic construct SF91
containing the identical leader sequence (Figure 1C
and D). Comparison of the two 50ss using the HBond
A B
C D
Figure 1. Dual attenuation of a 50ss via the structure and a mismatch at position +6. (A) Schematic drawing of the murine leukemia provirus. The
retrovirus is characterized by the long terminal repeats (LTRs, open boxes), the presence of the genes gag, pol and env (grey boxes) and the primer
binding site (PBS). The packaging signal (c) and the gag/pol reading frame are ﬂanked by 50 and 30ss. Below this, the MLV-derived splicing reporter
SF91 is depicted. The proviral 30ss was cloned downstream of the packaging signal and upstream of the eGFP start codon (grey box). Therefore,
SF91 encodes a genomic RNA (black line), which contains an intron constituted by the authentic MLV splice sites. (B) RNA secondary structure of
the region upstream of the packaging signal. The structure is adapted from the chemically validated structure (77). The regions R and U5 are part of
the LTR. The nucleotides representing the primer binding site and the 50ss are highlighted by open and grey circles, respectively. At the 50ss, the
+6C to U mutation is marked on the right. In the central region of the stem, the structural mutant sm3 including the nucleotide exchanges is
depicted. The inset shows the MLV 50ss pairing to U1 snRNA. Base pairs are indicated by vertical lines. (C) Northern blot using 10mg total RNA
from 293T cells transiently transfected with 5mg of the indicated constructs and harvested 48h post-transfection. The blot was hybridized with an
eGFP-speciﬁc probe. The identity of the RNA species is stated on the right. As a loading control, the blot was re-hybridized with a probe
corresponding to 18S rRNA. (D) Phosphoimager analysis of northern blot as shown in (C). The extent of alternative splicing is given as a
percentage of unspliced RNA (grey bars). The black bars represent quantitative RT-PCR analysis of the same RNA as in C. The primers to
detect the unspliced RNA are shown as thick black lines in (A). For detection of the spliced RNA, the same forward primer was used in combination
with an exon junction primer (primer position not shown). The mean values and standard deviations of three independent experiments are given.
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intrinsically weaker than MLV (HIV HBond score 15.7;
MLV HBond score 17.1). This is in agreement with our
hypothesis that a 50ss with lower complementarity should
be even more prone to attenuation via the RNA secondary
structure. Moreover, the mode of splicing regulation could
be transferred onto a heterologous 50ss since the sm3
mutant is spliced more eﬃciently and a deletion of the
PBS leads to more unspliced RNA (Figure 3D, compare
columns 3 and 4). Furthermore, no downstream MLV-
derived sequences were involved in 50ss attenuation. We
noted that the sm3 mutant did not splice to the same
extent as NLCenv, although the 50ss should be accessible
to the spliceosome (Figure 3C and D). However, this can
be explained by a purine-rich splicing enhancer present
only in the HIV leader sequence upstream of the 50ss
(39,46). In addition, the degree of splice site attenuation
inﬂuenced the total amount of RNA (Figure 3C). The
dPBS mutant in particular displayed the highest level of
unspliced RNA, but the lowest amount of RNA
(Figure 3C, lanes 5 and 6). In order to visualize the ratio
of unspliced vs. spliced RNA, this part of the northern
blot had to be overexposed (Figure 3C, lane 6).
The experiments using the HIV env expression
system demonstrate that the splicing regulation observed
is not restricted to MLV, but can be transferred to a
heterologous 50ss.
Replacement of the RNA structure with random sequences
capable of stem formation results in proper splicing
regulation
In order to diﬀerentiate whether mere structural
requirements of the leader region or speciﬁc sequences
harboring splicing regulatory protein binding sites cause
50ss attenuation, we replaced the upper part of the RNA
structure with a heterologous stem–loop harboring the
ability to form a stem with free energy similar to that of
the wild type (Figures 1B and 4A; SF91: G=–49.6kcal/
mol; heterologous stem–loop: G=–47.2kcal/mol).
RNA analysis of transient transfection of the stem–loop
construct revealed a splicing pattern almost identical to
that of the wild-type reporter (Figure 4B, lanes 1 and 2).
Thus, 50ss attenuation can be attributed to RNA stem–
loop formation and not to the primary sequence, which
forms the structure. As a control, we reversed the
descending part of the stem, resulting in a stem–loop
antisense (as) construct, which is unable to form the
secondary structure upstream of the 50ss. This construct
displayed complete splicing (Figure 4B, lane 3). In
contrast, strengthening the stem by a 20-bp extension on
either side (G=–68.8kcal/mol) led to more unspliced
RNA (Figure 4B and C; lane 4), reminiscent of the
deletion of the PBS (Figure 1C, lane 5). Furthermore,
the C6U mutation enhances splicing as in the wild-type
context, suggesting that this interplay does not require
speciﬁc cellular proteins binding to the MLV stem loop
(Figure 4B, lane 5). In addition, we noted that, similar to
the SCSenv plasmid (Figure 3C), the splicing eﬃciency
correlated with the overall transcript levels (Figure 4B,
compare lanes 3 and 4). Therefore, the lane containing
the stem–loop antisense (as) was underloaded for proper
visualization (Figure 4B, lane 3). The antisense mutant
showed that the 50ss could function highly eﬃciently in
the absence of the stem–loop despite the mismatch at
position +6. This position became only critical in
conjunction with the secondary structure, pointing to a
novel dynamic interplay between structure and primary
splice site sequence.
SR protein domains targeted to the heterologous
stem–loop partially overcome 5’ss attenuation
It has been shown in yeast that 50 and 30ss mutations can
be rescued by SR proteins even though Saccharomyces
cerevisiae does not code for such proteins (47). This
hints at a mechanism where SR proteins might stabilize
AB
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Figure 2. Splicing regulation is transferable to a complete provirus.
(A) Northern blot of 10mg of total RNA from 293T cells transfected
with 10mg of the proviral constructs (Figure 1A) harboring two splicing
mutants (sm3 and C6U; Figure 1B and C). Size standard is given on
the left and the RNA species are named on the right. (B) Western blot
analysis of the same transfection as in (A). Twenty micrograms of
protein were separated on a 10% SDS–PAGE and MLV-capsid
protein was detected using a polyclonal anti-capsid serum. The
polyprotein (Pr65) and the mature capsid protein (p30) are labeled
on the right. Re-probing with actin-speciﬁc antibody served as
loading control. (C) Phosphoimager analysis. The extent of splicing is
given as the percentage of unspliced RNA. The mean values and
standard deviations of three independent experiments are shown. (D)
Supernatants from transient transfections were adjusted in titer and
used to infect murine SC-1 cells. At the peak of infection, supernatants
were collected and re-titrated on SC-1 cells. The titer is expressed as
transducing units/ml in log scale. Three independent infections were
performed for each construct.
7434 Nucleic Acids Research, 2009, Vol. 37,No. 22RNA:RNA interactions at weak splice sites. Since the
secondary structure may restrict access to U1 snRNP,
we anticipated that targeting an SR protein into the
vicinity of the 50ss would overcome this attenuation by
supporting 50ss:U1 snRNA duplex formation. Tethering
of protein domains to an RNA of interest became
possible with the MS2-fusion tethering system (48,49).
The coat protein of the MS2 phage binds with high
aﬃnity to its target sequence, which is a short RNA
stem–loop (Figure 5A). However, due to structural con-
straints, our heterologous RNA stem–loop accommodates
only one MS2 binding site. We therefore used the FG
variant of the MS2 coat protein, which leads to an
increase in RNA binding aﬃnity at the expense of
dimer:dimer formation (50). This modiﬁcation should
theoretically result in enhanced binding to a single site
in vivo (Figure 5A). In a co-transfection assay, we tested
activation domains (RS domains) of various SR proteins
fused to MS2FG along with the SF91 construct and two
RNA stem–loop variants harboring a single MS2 binding
site (Figure 5B). Transfection of SF91 and a plasmid
encoding the RS domain of SRp55 fused to MS2FG
is not neutral, as observed for SF91, and leads to
a slight statistically signiﬁcant enhancement of splicing
(Figure 5B, lanes 1 and 2 and Figure 5C, P-value=
0.03). However, in the context of the RNA stem–loop
and the extended stem–loop construct, co-transfection of
the MS2-SRp55 plasmid led to a highly signiﬁcant
enhancement of splicing (Figure 5B and C, compare
lanes 3–6; P-value=0.009 and 0.002).
In general, these experiments proved for the ﬁrst time
in vivo that MS2FG mutants can be targeted to a single
binding site with reasonable eﬃciency. Moreover,
tethering of an RS domain to the heterologous RNA
AB
C
D
Figure 3. The MLV secondary structure is able to repress an HIV 50ss. (A) Schematic drawing of the NLCenv plasmid. NLCenv is derived from the
HIV molecular clone NL4-3. Expression is directed by the authentic LTR sequences except that the HIV promoter was replaced by CMV. ORFs are
shown as boxes. The splice sites are indicated as well as the primer binding site. Below this, the hybrid construct SCSenv is shown. The grey region
highlights the SF91-derived sequence in the HIV backbone. (B) The lower part of the secondary structure of MLV/HIV fusion transcript is shown.
The HIV 50ss is highlighted by grey circles and additional HIV-derived sequences as open circles. The HIV 50ss is forced into an inhibitory
conﬁrmation due to the upstream MLV stem loop. (C) Northern blot of 10mg of total RNA from HeLaP4 cells transiently transfected with
2.75mg of the indicated constructs. Two splicing mutations were transferred to SCSenv (sm3 and dPBS; Figure 1B). The RNA species are named
on the right. The lane containing SCSenv dPBS was overexposed to display the ratio between unspliced and spliced RNA (lane 6).
(D) Phosphoimager analysis as described in Figure 2C. The mean values and standard deviations of ﬁve independent experiments are shown.
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agreement with previous results that the RNA structure
may restrict access to U1 snRNP.
5’ splice site attenuation can be rescued by hyperstable
U1 snRNA suppressor mutants
In addition to protein:protein contacts of U1 snRNP with
exonic or intronic sequences (51,52), recognition of 50ss is
initiated by RNA:RNA interactions (9,53). Therefore, the
hydrogen bonding pattern between U1 snRNA and the
50ss is critical and can either be enhanced by mutations
within the 50ss (C6U mutation, Figure 1C, lane 2) or by
overexpression of U1 snRNA suppressor mutants that
increase the complementarity to a given 50ss (9,54).
In yeast, hyperstable U1 snRNA mutants cannot be
displaced by U6 snRNA and therefore splicing is
inhibited (55). In contrast, in mammalian cells, an
extended U1 snRNA/50ss interaction does not decrease
splicing eﬃciency, but rather increases 50ss recogni-
tion (56,57). We constructed two U1 snRNA mutants
containing one substitution (U1 G11C) leading to eight
complementary base pairs with the MLV 50ss
(Figure 6A; HBond score 18.8) or a perfect match of U1
snRNA leading to 11 continuous base pairs (U1 perfect;
Figure 6A; HBond score 23.8). Overexpression of these
suppressor mutants led to an increase in splicing
depending on the intrinsic strength of the RNA duplex
(Figure 6B and C). An increase in complementarity of
one base pair (U1 G11C mutant, Figure 6A, lower
panel) already led to an enhancement of splicing
(Figure 6C). This argues for a dynamic balance between
secondary structure and accessibility of the 50ss to U1
snRNA. As a control, we co-transfected the structural
sm3 mutant along with the U1 perfect suppressor
snRNA and observed no change in the enhancement of
splicing (Supplementary Figure 1).
In addition, we looked at direct interaction between
U1 snRNP and the 50ss in vitro by EMSA. In order to
minimize unspeciﬁc protein:RNA interactions, we used
the heterologous stem–loop and the antisense mutant
thereof as depicted in Figure 4A. We ﬁrst established
conditions that permit folding of the secondary
structure, but not of the antisense mutant (Figure 6D,
lanes 1 and 2). Under denaturing conditions, both
RNAs showed a similar migration behavior (data not
shown). Puriﬁed U1 snRNP was incubated with the
in vitro transcribed,
32P-labeled and folded RNA. We
observed an enhanced binding of U1 snRNP to the 50ss
in the absence of the RNA secondary structure (i.e. the
antisense mutant, Figure 6D, lanes 4, 6 and 8) and reduced
binding upon formation of the structure (Figure 6D, lanes
3, 5 and 7).
These experiments demonstrate that splicing regulation
in MLV uses restricted access of U1 snRNP to the 50ss
exerted by the upstream secondary structure and limited
complementarity of the primary 50ss sequence to U1
snRNA.
DISCUSSION
As presented here, murine leukemia virus uses a dynamic
interplay between RNA secondary structure and the
intrinsic strength of the 50ss to restrict access of U1
snRNP to its 50ss, which ultimately results in alternative
splicing and full viral gene expression.
Secondary structure has been implicated in alternative
splicing early on (18,58–60). Cellular examples of
attenuated 50ss, which are part of a secondary structure,
were discovered in association with diﬀerent genetic
diseases (56,61,62). Modulation of splicing eﬃciency by
RNA secondary structures has recently also been
described for the HIV-1 leader RNA structure, where
the major 50ss is embedded in a semi-stable hairpin (63).
However, contrary to HIV-1, splicing regulation at the
MLV 50ss seems to be much more complex, since stem
mutations even 25nt upstream of the 50ss already
provoke an 8-fold enhancement of splicing (Figure 1).
Certainly, secondary structures cannot only sequester
50ss, but also modulate the binding eﬃciency of hnRNPs
or SR proteins. On a global scale, it was shown that
splicing enhancers and silencers are present mostly in
single-stranded regions (64). There is also a particular
AB
C
Figure 4. A heterologous stem–loop substitutes for the MLV secondary
structure. (A) The secondary structure is depicted as in Figure 1B. The
horizontal black line marks the insertion of heterologous sequences
forming the synthetic stem–loop. On each side of the stem an EcoRI
restriction site is indicated. The 50ss is highlighted by grey circles.
(B) Northern blot analysis of 10mg total RNA from transfected 293T
cells. The RNA species are marked on the right. Note that only 5mg
RNA were loaded in the stem–loop antisense (as) lane due to the high
expression of this construct. (C) Phosphoimager analysis. Mean values
and standard deviation represent three independent experiments.
7436 Nucleic Acids Research, 2009, Vol. 37,No. 22example in HIV, where a change in secondary structure
allows hnRNP H to bind and inﬂuence splicing (65). RNA
secondary structures are also statistically associated with
alternative 50ss (66), allowing splice site selection via
conformational variability.
An exchange of the upper part of the structure with
a heterologous stem–loop proved that the main function
of the stem is to force the 50ss into an inhibitory
conformation and the extent of splicing inhibition
correlates closely with the free energy of the structure
(Figure 4). Thus, the secondary structure can be viewed
as a silencer element, which converts a strong 50ss into
a weak one. Not surprisingly, the complex RNA stem–
loop possesses additional functions in the viral life cycle.
The structure allows looping of the primer binding site,
which binds a cellular tRNA as a primer to initiate reverse
transcription (3). Yet, splicing regulation could be
transferred to a complete provirus and to a heterologous
HIV 50ss (Figures 2 and 3). Using the MLV/HIV hybrid
plasmids, it seemed that the degree of 50ss inhibition
correlates inversely with the overall RNA amount
(Figure 3C). Similar eﬀects have been observed in other
studies, where splice sites are able to enhance
transcriptional elongation (67) and gene expression in
general (68). It appears that the CMV promoter is
highly dependent on this positive feedback exerted by
the interaction of U1 snRNP with a proximal 50ss
(69,70). This suggested to us that the secondary structure
restricts access of U1 snRNP. Additional evidence was
obtained by tethering RS domains to the heterologous
stem–loop, which enhanced splicing (Figure 5). The
relatively modest eﬀects are most probably due to the
insertion of only a single MS2 binding site (Figure 5A).
The MS2FG mutants used here can partly compensate
AB
C
Figure 5. An RS domain can partially relieve 50ss attenuation. (A) Depiction of the heterologous stem–loop structure as in Figure 4A. In addition to
the 50ss, the MS2 binding site is highlighted by open circles. MS2-RS fusion proteins recognize the MS2 binding site as dimers. (B) Northern blot
performed as in Figure 1C. As a control, a plasmid encoding only the MS2 coat protein was co-transfected as indicated. The RS domain of SRp55
was fused to the modiﬁed MS2 protein. The RNA species are marked on the right. (C) Phosphoimager analysis. Splicing eﬃciency is displayed as
unspliced/spliced RNA ratio. Student’s t-test was performed using mean values from four independent experiments.  P=0.03;   P=0.009;
   P=0.002.
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play a dual role in splice site selection. They can
enhance RNA:RNA interactions at degenerated splice
sites (47,71) or engage in protein:protein interactions,
since an excess of SR proteins can select 50ss in the
absence of U1 snRNP (72). In our case, the RS domain
may directly assist U1 snRNA binding to the attenuated
50ss by interacting with U1-70K (73).
In addition, the retroviral 50ss is characterized by a
mismatch at position +6. Reversion of this position into
a complementary nucleotide to U1 snRNA enhances
splicing 2.5-fold. Although this position is less conserved
on a genome scale, it turns into a preserved nucleotide if
the 50ss is degenerated or weakened by surrounding
elements (10). For example, a U6C mutation in the 50ss
ﬂanking exon 20 of the IKBKAP gene causes exon
skipping, resulting in familial dysautonomia (74). In this
case, pre-existing attenuation is due to a weak upstream
30ss and possible splicing silencers (75). An additional
weakening of the 50ss ﬁnally results in the disease-
causing splicing phenotype. In this line, position +6 of
the MLV 50ss regulates eﬃciency only in the context of
the secondary structure. Therefore, there is a dynamic
interplay between structure and the 50ss sequence, where
the structure makes the 50ss susceptible to silencing as it
was observed for cellular silencer motifs (76). The same
result was obtained when we fused the complete second
intron from b-globin to the MLV secondary structure.
Alternative splicing occurred only after lowering the
complementarity at positions +6 or  3 of the globin
50ss (Zychlinski,D. and Bohne,J. unpublished data). We
also mutated positions +7 and +8 of the MLV 50ss
back to the consensus and observed an enhancement of
splicing (data not shown). However, the enhancement
was not as strong as observed for position +6. One may
speculate that not solely complementarity to U1 snRNA,
but also the length and neighborhood of the 50ss:U1
snRNA duplex determine the strength of a splice site.
This novel dynamic interplay of RNA secondary
structure and low complementarity to U1 snRNA of the
AB
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Figure 6. Hyperstable U1 snRNA suppressor mutants enhance splicing. (A) The top line shows the MLV 50ss. Possible base pairs to U1 snRNA are
indicated by vertical lines. In the middle and lower panel, pairing of the MLV 50ss with the two U1 snRNA mutants is depicted. Mutated nucleotides
in U1 snRNA are in bold. On the right-hand side, the HBond score (HBS) is given. (B) Northern blot using 10mg of total RNA from transiently
transfected 293T cells. Transfections were performed using 5mg of SF91 plasmid and 10mg of the respective U1 snRNA plasmid. The RNA species
are named on the right. (C) Phosphoimager analysis. The eﬃciency of splicing is shown as the relative level of unspliced RNA. SF91 in the presence
of co-transfected U1wt plasmid was set to 1. Mean values and standard deviations represent ﬁve independent experiments. (D) Mobility shift assay
using in vitro transcribed,
32P-labeled and folded MLV RNA depicted in Figure 4A. The RNAs were incubated with increasing amounts of puriﬁed
U1 snRNP (50ng, 125ng and 250ng).
7438 Nucleic Acids Research, 2009, Vol. 37,No. 2250ss demonstrates the ﬁne-tuning of alternative splicing in
retroviruses and mammalian cells and illustrates the
sophisticated organization of the splicing code.
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